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A B S T R A C T 
Medication overuse headache, which affects patients 
who have migraines and frequent headaches, is 
prevalent worldwide and can severely impact daily 
functioning. Medication overuse headache is often 
not recognised by primary care physicians or general 
practitioners, as patients may overuse medications that 
are freely available without a prescription. Overuse 
of codeine-containing analgesics is particularly 
problematic and contributes to ongoing morbidity 
and opioid-related mortality. This article aims to 
provide an overview of the detection, prevention, 
and management of medication overuse headache. 
The definition of medication overuse headache 
and the risk levels of commonly used symptomatic 
headache medications are presented. An algorithm 
consisting of a number of simple questions can assist 
general practitioners with identifying at-risk patients. 
Treatment strategies are discussed in the context of a 
multidisciplinary approach.
Medication overuse headache: strategies 
for prevention and treatment using a 
multidisciplinary approach
The estimated prevalence of medication overuse 
headache (MOH) in the general population ranges 
from 0.6% to 7%.1-8 A number of acute headache 
treatments may cause MOH,7 and the medications 
that are predominantly associated with MOH vary 
from country to country.1,7,9,10 Opioids such as codeine 
are particularly problematic, as they are consistently 
associated with increasingly severe headaches11 
(Table12) and poor outcomes after withdrawal.13 In a 
number of regions, including Hong Kong and Japan, 
codeine-containing medication is only available 
by prescription.14 In Australia, beginning in 2018, 
codeine (and its combinations with simple analgesics) 
will only be available by prescription, following a 
2015 decision by the Australian Therapeutic Goods 
Administration (TGA).15 This policy change is 
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supported by evidence demonstrating an increase in 
unintentional codeine-related deaths in Australia.16
 A systematic analysis of the global, regional, 
and national burden of neurological disorders from 
1990 to 2015 (using data from the Global Burden 
of Disease Study 2015) found that neurological 
disorders were the leading cause of disability-
adjusted life years (DALYs) in 2015, with the most 
prevalent neurological disorders being tension-
type headache (1505.9 million DALYs), migraine 
(958.8 million DALYs), and MOH (58.5 million 
DALYs).17 As large numbers of people are potentially 
at risk of MOH, including anyone with frequent 
primary episodic headaches, strategies for primary 
prevention, treatment, and prevention of relapse 
may have substantial public health benefits.
MEDICAL PRACTICECME
TABLE.  Risk of MOH from symptomatic headache medications12










Abbreviations: MOH = medication overuse headache; NSAIDs = nonsteroidal anti-inflammatory drugs
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Definition of medication overuse 
headache
The definition of MOH is headache occurring on ≥15 
days per month as a consequence of regular overuse 
of acute or symptomatic headache medication 
(≥10 days per month for triptans, ergotamines, or 
opioids; ≥15 days per month for simple or combined 
analgesics) for more than 3 months. It usually, but 
not invariably, resolves after the overuse is stopped.18
Problems with detection and 
treatment of medication overuse 
headache
Patients’ lack of awareness of medication overuse 
as a cause of headaches, reluctance to acknowledge 
how much medication they take, and poor adherence 
to recommended treatment have been identified 
as barriers to detection and management of MOH. 
A survey of Australian general practitioners 
(GPs)19 showed that GPs’ awareness of MOH is 
low, although the awareness of codeine overuse in 
general may have increased following the TGA’s 
decision, which was widely discussed in the media. 
In Singapore, a general practice survey of patients 
and their attending physicians in a primary care 
setting found that 22.6% of the patient population 
reported taking acute pain medication for headaches 
at least 4 days per week. However, the physicians 
only identified this in 5.3% of the study population, 
indicating that physicians did not recognise a large 
percentage of patients at risk of MOH.20 Khu et al20 
commented that overuse of analgesic medications 
may lead to ‘doctor-hopping’ by patients in search 
of increasingly elusive headache relief. There may 
be a need to provide greater awareness of MOH 
during medical training, as a survey of final year 
medical students in Singapore found that 47% were 
unfamiliar with MOH as a disease entity, and 96% 
were unfamiliar with local clinical practice guidelines 
about headaches.21
 Patients with frequent episodic migraines 
(headaches on 8-15 days per month) or chronic 
migraines (headaches on >15 days per month) 
are at particular risk of developing MOH. General 
practitioners play a crucial role in identifying these 
patients, assessing their medication intake, and 
offering strategies to minimise the risk of MOH (Box 
14,22).
 Patients may be reluctant to reveal how 
many analgesics they take or may be unaware or 
unwilling to accept that the medication they use to 
treat their headaches is actually contributing to the 
continuation of their headaches. They may also be 
reluctant to discontinue medication that they have 
found to provide some relief for their headaches 
in the past. Patients who are anxious about their 
headaches interfering with essential activities, 
such as work, may use medication routinely as 
a preventive measure. In addition, a common 
misperception among consumers is that medication 
that can be purchased without a prescription (‘over 
the counter’) is harmless.23 Unfortunately, once 
established, MOH (particularly that caused by 
opioids) has a high relapse rate after treatment.24 
Adherence to recommended treatment is generally 
suboptimal in patients with MOH, but the majority 
of relapses occur in the first year after withdrawal.25 
It is therefore important to educate patients about 
the pathophysiology and treatment of MOH and to 
continue supporting them beyond the immediate 
period of withdrawal.
 Some patients who report “excessive” 
medication use and very frequent headache do not 
respond to medication withdrawal. Patients who 
develop MOH are usually those with intrinsically 
high-frequency headaches, and withdrawal tends 
to lead to reversion to their natural background 
headache pattern, which may range from infrequent 
episodic migraines to higher-frequency patterns. 
Scher et al26 questioned the benefit of withdrawal 
or restriction of medication on the grounds that the 
patient may not benefit from it. However, withdrawal 
allows the underlying headache pattern to be 
determined and a reappraisal of headache control to 
be conducted. Study results have demonstrated that 
withdrawal of headache medication benefits many 
patients with MOH. For example, in a recent study, 
patients diagnosed with MOH were randomised 
to 2 months’ detoxification with either complete 
withdrawal of medication or acute medication 
restricted to 2 days/week. The number of migraine-
days/month was significantly reduced after 6 months 
with both treatments, with a greater reduction of 
migraine-days/month in the complete withdrawal 
group, indicating that complete withdrawal is 
generally more effective than medication restriction 
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and that medication overuse was a major factor in 
the patients’ headache pathology.27
A multidisciplinary approach
As patients with MOH often do not present to their 
GPs in response to the first instance, pharmacists 
can play a role in educating patients who self-
medicate with analgesics when analgesics are 
purchased without a prescription.28 They could 
encourage patients who may be overusing pain 
relief medication to consult their GPs to discuss 
other treatment options. However, it may not be 
easy to identify at-risk patients, as some obtain large 
quantities of headache medications by shopping at 
different pharmacies. Identification of these patients 
could be facilitated by using a tracking system to 
detect patients who buy headache medication at 
multiple pharmacies.
 Conditions associated with self-medication, 
such as MOH, could be prevented by community 
pharmacists. Community pharmacists have 
overviews of both prescriptions and non-prescription 
medications that patients are taking (provided that 
patients are not visiting several different pharmacies) 
and are easily accessible to patients.29,30 Thus, the 
sale of headache medications is an opportunity to 
discuss their potential adverse effects and their role 
in MOH. A survey in Japan on the role of community 
pharmacists in self-medication of patients with 
headache found that 32% of the surveyed doctors 
were concerned about the increase of patients who 
overuse headache medication. Both doctors and 
pharmacists thought that pharmacists should not 
only provide patients with “instruction on the use of 
drugs” but also suggest “when to consult a hospital 
or clinic”.31 However, strategies may need to be 
devised to motivate patients to do this, as another 
Japanese survey of pharmacists and doctors found 
that 22% of pharmacists had experienced refusal by 
patients with headache to consult a clinic, despite 
the pharmacist’s recommendation.32
 Community pharmacists have an important 
role in supporting patients with headache. This can 
be fostered by all key stakeholders—pharmacists, 
doctors, and patients—being provided with 
multidisciplinary opportunities to improve their 
MOH health literacy and to maintain an open and 
collaborative relationship.
 Although MOH often develops outside of GPs’ 
immediate view through patients’ self-medication, 
GPs are important in its prevention, detection, 
and treatment. The first step is educating patients, 
and when they do not understand the cause of and 
treatment for MOH, taking time to inform them and 
clarify their misunderstandings.29 The next step is to 
develop a plan with the patient and provide clear and 
continuing support for what is often a challenging 
journey. General practitioners also need to be aware 
of situations in which patients should be referred 
to a neurologist, preferably one who specialises in 
headache management.
 Discussions between GPs or pharmacists and 
patients who overuse headache medication are often 
1. Recognising migraine
Use the three-question ID Migraine tool as a useful screener.22 If the answer to two or three of the questions below is 
“yes”, the diagnosis is very likely to be migraine:
(i) In the past 3 months, has a headache interfered with your activities on at least one day?
(ii) When you have a headache, do you feel nauseated (sick)?
(iii) When you have a headache, does light bother you?
Once a diagnosis of migraine is suspected, count headache days and medication days and employ strategies to 
minimise the risk of MOH.
Counting headache days
“How many days per month do you have a headache?”, or better,
“How many days per month do you have no headache at all?”
Counting medication days
“How many days per month do you take medication for headaches?”, or
“How many days per month do you take no medication for headaches at all?”
2. Minimising the risk of MOH in patients with frequent migraines:
•	 Introduce	appropriate	migraine	prophylaxis4
•	 Use	a	staged	approach	to	acute	headache	treatments:
o Use NSAIDs or simple analgesics for mild headaches
o Use triptans for more severe headaches (but not >10 days per month)
o Avoid codeine-containing medications
BOX 1.  Practical strategies for avoiding MOH
Abbreviations: MOH = medication overuse headache; NSAIDs = nonsteroidal anti-inflammatory drugs
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delicate. The patient may perceive an accusation of 
‘recreational use’ of (particularly codeine-containing) 
drugs. It is vital for productive communication that 
the health care professional clarify that there is no 
suspicion of this type and that the medications are 
recognised as being used to deal with genuinely 
troublesome symptoms. It is vital to subsequently 
emphasise that ongoing use of particular headache 
medications may contribute to perpetuation of 
headaches and that better strategies are available.
Management and prevention 
strategies
Prevention of headaches is better than curing 
them. Pharmacists and GPs who are aware of MOH 
can detect patients with increasing frequencies 
of headaches and medication use. Strategies to 
assist such patients before they progress into frank 
MOH include lifestyle adjustments and appropriate 
prophylaxis, as discussed below as part of MOH 
treatment (Box 2).
 Complete withdrawal from overused headache 
medications is a key component of the management 
strategy, along with education, counselling, and 
support. Abrupt withdrawal is usually preferred, 
but tapered withdrawal may be more appropriate 
when codeine is implicated.25 Coexisting psychiatric 
conditions should also be assessed and managed. As 
medication discontinuation results in withdrawal 
headaches—often associated with nausea, vomiting, 
and sleep disturbance—patients frequently need 
assistance coping with withdrawal symptoms and 
persevering with discontinuation.4,12,33,34 Symptoms 
usually last between 2 and 10 days, with withdrawal 
from triptans lasting approximately 4 days and that 
from nonsteroidal anti-inflammatory drugs lasting 
about 10 days. Withdrawal can be managed through 
primary care; however, opioid discontinuation may 
require hospitalisation.34,35
 Accurate diagnosis based on the third edition 
of the International Classification of Headache 
Disorders17 and referral of complex cases to a 
neurologist/headache specialist is recommended for 
individualised treatments. Psychiatric assessment 
may also be indicated in some cases. However, in 
many countries, limited specialist availability means 
that referrals need to be selective. Psychologists and 
physical therapists have a role, as psychotherapy, 
relaxation techniques, physical exercise, and 
cognitive behaviour therapy may be useful adjuncts 
to supervised pharmacotherapy.4,12,23,28,34,36,37 
The combination of behavioural treatment and 
prophylactic medication may significantly reduce 
the risk of relapse.37 Preventive medications for 
chronic migraines include antiepileptic drugs 
(particularly topiramate), antidepressants (eg, 
amitriptyline), onabotulinum toxin A, and drugs 
used for episodic migraines (eg, beta blockers). For 
example, topiramate (oral) and onabotulinum toxin 
A (by local injection) are recommended by the 
Taiwan Headache Society 2017 medical treatment 
guidelines as first-line treatments for prophylaxis 
of chronic migraines.38 Education about acute and 
prophylactic treatment may improve adherence to 
both pharmacological and non-pharmacological 
therapies.28
 In some circumstances, withdrawal may 
require hospital admission. Patients with MOH 
who have been detoxified as in-patients should be 
followed up by their GPs. Support by a headache 
nurse (available in some neurological practices) can 
improve adherence to detoxification.39
 Multidisciplinary treatment of patients with 
MOH, including pharmacological prophylaxis, 
relaxation therapy, and aerobic sports, is 
associated with reduction in headaches, as long as 
patients adhere to the recommended therapies.28 
Motivational telephone interviewing may also help 
to promote adherence.40 To supplement regular GP 
support, practice nurses could be involved in patient 
support, and they could liaise with pharmacists to 
monitor medication use.
Conclusion
There is an urgent need for increased awareness 
of MOH among both patients and health care 
professionals.41 Medication overuse headache causes 
considerable morbidity but is preventable. Headache 
frequency (and the associated disability, depression, 
and anxiety) can be considerably reduced in patients 
with MOH through withdrawal from the overused 
medication and appropriate supportive treatment. 





2. Provide education on MOH and expected withdrawal symptoms




4. Use a multidisciplinary team
•	 Counselling
•	 Physiotherapy
5. Monitor progress by:
•	 counting	headache	days	(please	refer	to	Box	1)
•	 counting	medication	days	(please	refer	to	Box	1)
6. Offer regular follow-up and support through GPs or headache nurses
7. Collaborate with local community pharmacies where feasible
BOX 2.  Treatment strategies for patients with MOH (abrupt withdrawal with 
immediate initiation of prophylactic medication)
Abbreviations: GPs = general practitioners; MOH = medication overuse headache; 
NSAIDs = nonsteroidal anti-inflammatory drugs
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A multidisciplinary approach involving primary 
care physicians (GPs), community pharmacists, 
nurses, and allied health providers,36 with referral to 
neurologists/headache specialists (where available) 
for complex cases, is recommended.
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